Stryker Co. (NYSE:SYK) Shares Sold by JLB & Associates Inc.

JLB & Associates Inc. trimmed its position in Stryker Co. (NYSE:SYK) by 1.2% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,379 shares of the medical technology company’s stock after selling 365 shares during the period. JLB & Associates Inc.’s holdings in Stryker were worth $10,613,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Aspen Investment Management Inc increased its holdings in shares of Stryker by 0.7% in the 1st quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock valued at $1,563,000 after acquiring an additional 31 shares during the last quarter. Harbor Investment Advisory LLC grew its position in shares of Stryker by 0.4% during the 1st quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock valued at $2,499,000 after buying an additional 31 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in Stryker by 2.4% in the first quarter. Proficio Capital Partners LLC now owns 1,418 shares of the medical technology company’s stock worth $507,000 after acquiring an additional 33 shares during the last quarter. Versant Capital Management Inc grew its holdings in shares of Stryker by 4.0% during the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 33 shares during the last quarter. Finally, Stanley Laman Group Ltd. lifted its holdings in shares of Stryker by 4.6% in the 2nd quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company’s stock worth $256,000 after purchasing an additional 33 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on SYK shares. Royal Bank of Canada restated an “outperform” rating and issued a $386.00 target price on shares of Stryker in a research report on Wednesday, July 31st. UBS Group increased their price objective on shares of Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday. Piper Sandler restated an “overweight” rating and issued a $380.00 price target on shares of Stryker in a research report on Tuesday, September 10th. Finally, Evercore ISI boosted their price objective on Stryker from $365.00 to $380.00 and gave the stock an “outperform” rating in a report on Tuesday. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $379.37.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at $3,685,213.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Stryker news, insider Viju Menon sold 600 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. The disclosure for this sale can be found here. In the last three months, insiders sold 220,068 shares of company stock valued at $71,811,372. Company insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.6 %

Shares of Stryker stock opened at $355.11 on Thursday. The company has a market cap of $135.28 billion, a price-to-earnings ratio of 40.54, a PEG ratio of 2.78 and a beta of 0.91. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $374.63. The company’s fifty day simple moving average is $348.90 and its 200-day simple moving average is $343.12. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The business had revenue of $5.42 billion during the quarter, compared to analyst estimates of $5.40 billion. During the same quarter in the prior year, the business earned $2.54 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, sell-side analysts expect that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.90%. Stryker’s payout ratio is 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.